scispace - formally typeset
L

Leopold Sellner

Researcher at Takeda Pharmaceutical Company

Publications -  60
Citations -  1734

Leopold Sellner is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Chronic lymphocytic leukemia & T cell. The author has an hindex of 21, co-authored 58 publications receiving 1256 citations. Previous affiliations of Leopold Sellner include University Hospital Heidelberg & Heidelberg University.

Papers
More filters
Journal ArticleDOI

Lysosome-Targeting Amplifiers of Reactive Oxygen Species as Anticancer Prodrugs.

TL;DR: This work proposes and validate a potentially general approach for solving the intrinsic problem of ROS-dependent prodrugs and finds it to exhibit high anticancer activity in a variety of cancer cell lines and in vivo.
Journal ArticleDOI

Drug-perturbation-based stratification of blood cancer

TL;DR: This study overcomes the perception that most mutations do not influence drug response of cancer, and points to an updated approach to understanding tumor biology, with implications for biomarker discovery and cancer care.
Journal ArticleDOI

Aminoferrocene-Based Prodrugs and Their Effects on Human Normal and Cancer Cells as Well as Bacterial Cells

TL;DR: It is demonstrated that the prodrugs are active against primary chronic lymphocytic leukemia (CLL) cells, with the best compounds exhibiting an IC50 value of 1.5 μM, and the most active compounds were found to not affect mononuclear cells and representative bacterial cells.